Predictive Oncology Completes AI-driven Study of Ovarian Cancer with UPMC Magee-Womens Hospital

2 years ago

PITTSBURGH, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics,…

Organovo Highlights FXR314 Combination Therapy Potential and Plan

2 years ago

SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is…

Avid Bioservices Partners With California Institute for Regenerative Medicine (CIRM) to Provide CDMO Services for Cell and Gene Therapy (CGT) Programs

2 years ago

CIRM-Funded Programs to Receive Access to Avid’s Suite of World-Class CGT CDMO Services to Support Clinical Development ActivitiesTUSTIN, Calif., Nov.…

Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights

2 years ago

Phase 1b Study of NXP800 in Patients with Platinum Resistant, ARID1a-Mutated Ovarian Carcinoma is Ongoing Initiated the Phase 1a Dose…

futuresTHRIVE Launches Game-Changing AI Platform to Transform Youth Mental Health Screening

2 years ago

Insights from Recent Research Study Expose Significant Gaps in Standard of CareDARIEN, Conn., Nov. 08, 2023 (GLOBE NEWSWIRE) -- futuresTHRIVE,…

Collegium to Participate in Upcoming Investor Conferences

2 years ago

STOUGHTON, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to…

Prime Medicine to Present at Upcoming Investor Conferences

2 years ago

Cambridge, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a…

Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences

2 years ago

BEDFORD, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development,…

PepGen Reports Third Quarter 2023 Financial Results and Recent Corporate Developments

2 years ago

- Continuing to open CONNECT1-EDO51 trial sites in Canada - - Opening of FREEDOM-DM1 trial sites underway in the U.S. and…

Erasca to Present at Upcoming Investor Conferences in November

2 years ago

SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on…